Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation

Autor:	Tobias Peikert, Yuh Min Chen, Yanan Yang, Henry D. Tazelaar, Yung Hung Luo, Han Liu, Shih Hwa Chiou, Konstantinos Leventakos, Ping Yang, Jason A. Wampfler, Dan Liu, Yalun Li
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Mutation Hematology biology business.industry General Medicine Lower risk medicine.disease_cause medicine.disease respiratory tract diseases T790M Internal medicine PD-L1 biology.protein Medicine Osimertinib Stage (cooking) business Lung cancer
Zdroj:	Journal of Cancer Research and Clinical Oncology. 148:2099-2114
ISSN:	1432-1335 0171-5216
DOI:	10.1007/s00432-021-03766-5
Popis:	The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice. 417 patients had stage III–IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed. Higher risk of death was found in EGFR-mutant patients with age ≥ 65 years, non-adenocarcinoma, no surgery or radiation, non-exon 19 deletion/exon 21 L858R, higher ECOG PS (2–4), PD-L1 expression ≥ 50%, and bone/liver/adrenal metastasis (all p 10%, and PD-L1 expression ≥ 50% (All p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9afcb21b93f9af7975a7771178e82628 https://doi.org/10.1007/s00432-021-03766-5 Zobrazit plný text záznamu Full text from SpringerLink